title: Strategies for siRNA navigation to desired cells.
abstract: Whilst small interfering (si) RNAs have emerged as a promising therapeutic modality for treating a diversity of human diseases, delivery constitutes the most serious obstacle to siRNA drug development. As the most used delivery agents can enter all cell types, specificity must be built into the delivery agents or directly attached to the siRNA molecules. The use of antibodies, peptides, Peptide-Fc fusions, aptamers, and other targeting ligands has now enabled efficient gene silencing in the desired cell populations/tissues in vitro and in vivo. The present review summarizes these current innovations, which are important for the design of safe therapeutic siRNAs.
authors.affiliation: Departments of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, Radiumhospitalet-Rikshospitalet University Hospital, Ullernchausseen 70, Montebello, 310, Oslo, Norway, Mouldy.Sioud@rr-research.no.
authors.forename: Mouldy
authors.initials: M
authors.lastname: Sioud
mesh_terms: D000906:Antibodies / Q000737:chemistry / Q000378:metabolism; D052157:Aptamers, Nucleotide / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D001692:Biological Transport; D045744:Cell Line, Tumor; D004337:Drug Carriers; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D019151:Peptide Library; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics* / Q000378:metabolism; D052156:SELEX Aptamer Technique; D054852:Small Molecule Libraries / Q000737:chemistry / Q000378:metabolism; D000077022:Survivin
chemical_list: D000906:Antibodies; D052157:Aptamers, Nucleotide; C107489:BIRC5 protein, human; D004337:Drug Carriers; D051034:Inhibitor of Apoptosis Proteins; D019151:Peptide Library; D010455:Peptides; D034741:RNA, Small Interfering; D054852:Small Molecule Libraries; D000077022:Survivin